I oversee the Integrative Biology group within Pfizer's Internal Medicine Research Unit. We support Pfizer's drug discovery pipeline through the application of human genetics and computational biology knowledge, methods and tools including the analysis and mining of genetics, epigenetics, transcriptomics, metabolomics and proteomics experiments and resources to improve target identification, target selection, target validation, patient stratification, biomarker identification and biomarker validation. Over the past several years I have focused on the biological interpretation of GWAS data. My formal training is in structural biology and X-ray crystallography of proteins.